Oregon Measure 109 — Psilocybin therapy is legal and regulated in Oregon. Find a licensed facilitator →

Category

The neuroscience of psilocybin therapy

Peer-reviewed research on how psilocybin interacts with the brain — from default mode network disruption to long-term neuroplasticity. We cover the mechanisms, the imaging data, and what it means for treatment.

80+
Peer-Reviewed Studies
12
Active Clinical Trials
67%
PTSD Symptom Reduction
54%
Depression Remission Rate
4–6 hrs
Average duration of a therapeutic psilocybin session
OHA Session Guidelines, 2023
2–3×
Sessions typically used in clinical protocols for treatment-resistant depression
COMPASS Pathways Phase 2b, 2022
1 month
Window of heightened neuroplasticity observed post-session
Cahart-Harris et al., Nature, 2021
5-HT2A
Primary serotonin receptor targeted by psilocybin — distinct from SSRIs
Nichols, Pharmacol Rev, 2016
Latest Research
Recent studies and what they mean
01
The Default Mode Network: What Psilocybin Actually Does to the Brain
fMRI studies reveal how psilocybin disrupts the brain's most entrenched self-referential loops — and why that disruption may be the key to lasting change.
Dr. Sarah Chen·8 min
02
Neuroplasticity and the Post-Session Window: What the Data Shows
A review of structural and functional brain changes observed in the days and weeks following psilocybin administration — and how clinicians are learning to use them.
Dr. Marcus Lee·11 min
03
Psilocybin vs. SSRIs: What the Head-to-Head Trials Found
The COMPASS Pathways and Imperial College trials compared psilocybin directly against escitalopram for depression. The results are more nuanced than the headlines suggest.
Dr. Rachel Jensen·14 min

How psilocybin works — the short version

Psilocybin is a prodrug: the body converts it to psilocin, which binds primarily to 5-HT2A serotonin receptors in the prefrontal cortex. This binding disrupts the default mode network — a brain system associated with self-referential thinking, rumination, and rigid belief maintenance.

Unlike SSRIs, which modulate serotonin availability continuously, psilocybin produces a brief but profound change in brain connectivity. Regions that don't normally talk to each other begin communicating. Pathological patterns of rigidity temporarily dissolve.

The therapeutic window created by this disruption — typically 4–6 hours — is used by trained facilitators to help patients reprocess traumatic memories, shift entrenched beliefs, and access states of mind that are otherwise pharmacologically unreachable.

Key Concepts
What is the DMN?
The default mode network — active during self-referential thinking and rumination. Chronically overactive in depression and PTSD.
What is neuroplasticity?
The brain's ability to reorganize itself. Psilocybin appears to temporarily increase neuroplasticity, creating a window for therapeutic change.
Is psilocybin addictive?
No. Psilocybin shows no dependence potential in clinical or recreational use. It actually shows promise for treating addiction to other substances.
How is it different from MDMA therapy?
MDMA acts primarily on the amygdala and fear response. Psilocybin works more broadly through serotonin receptors and DMN disruption — different mechanisms, different indications.
Scroll to Top